Details of the Drug
General Information of Drug (ID: DM7BXHQ)
Drug Name |
GNF-PF-3878
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
143069-08-3; GNF-PF-3878; TCMDC-124255; 9-Acridinamine, N-(4-(4-ethyl-1-piperazinyl)phenyl)-; CHEMBL217366; N-(4-(4-Ethyl-1-piperazinyl)phenyl)-9-acridinamine; N-[4-(4-ethylpiperazin-1-yl)phenyl]acridin-9-amine; 9-Acridinamine,N-[4-(4-ethyl-1-piperazinyl)phenyl]-; N-(4-(4-ethylpiperazin-1-yl)phenyl)acridin-9-amine; CBDivE_005028; AC1MILKO; ACMC-20n23a; CTK4C3465; DTXSID10162300; BDBM50196122; AKOS030561802
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 382.5 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 5.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||